Skip to main content
    G

    Gilead Sciences Inc (GILD)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $170.26
    +2.68 (+1.60%)

    Market Cap: $207.86B

    Last updated: Nov 17, 2026 at 4:44 PM ET

    Gilead Sciences Inc (GILD) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Gilead Sciences (GILD) has a market cap of $207.86B and an enterprise value of $227.65B. It kept -12.47% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 9.52% above the market cap, as debt exceeds cash.

    Market Cap$207.86B
    Enterprise Value$227.65B
    Latest price (Nov 17, 2026)$170.26

    Key Dates

    The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Dec 15, 2026.

    Next Earnings DateFeb 8, 2027 (expected)
    Last Earnings DateOct 29, 2026
    Next Ex-Dividend DateDec 15, 2026
    Next Payment DateDec 30, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.08% in the quarter ended Sep 30, 2026 and shrank 0.20% a year over 2 years.

    Shares Outstanding1.24B
    Shares Change (YoY)-0.08%
    Shares Change (QoQ)-0.08%
    Share Count Growth (2Y CAGR)-0.20%

    Valuation Ratios

    Sales and book value multiples are 6.8x and 16.2x. Its year-end P/S ranged from 3.0x to 5.2x from 2016 to 2025.

    P/S Ratio6.8x
    Forward P/S6.6x
    P/B Ratio16.2x
    P/FCF Ratio15.3x
    P/OCF Ratio14.4x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 178.9x EBITDA and 16.8x free cash flow.

    EV / Sales7.3x
    EV / EBITDA178.9x
    EV / FCF16.8x

    Price Statistics

    The stock is up 37.86% over 52 weeks and trades 9.25% above its 50-day average.

    Beta (1Y)0.38
    52-Week Change+37.86%
    1-Month Change+11.23%
    3-Month Change+16.00%
    6-Month Change+32.06%
    5-Year Change+163.07%
    10-Year Change+131.81%
    Total Return (1Y)+40.49%
    Total Return (3Y CAGR)+34.25%
    Total Return (5Y CAGR)+23.98%
    Return vs SPY (1Y)+23.96%
    Max Drawdown (1Y)-22.02%
    Max Drawdown (3Y)-26.58%
    Sharpe Ratio (1Y)1.13
    Correlation with SPY (1Y)0.19
    50-Day Average$155.84
    200-Day Average$141.10
    52-Week Range$114.81 to $176.58
    RSI (14 Days)61.9
    Average Volume (20 Days)6.47M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.38x current liabilities, and total debt is 2.01x shareholder equity.

    Current Ratio1.38x
    Quick Ratio1.22x
    Debt / Equity2.01x
    Debt / EBITDA20.29x
    Debt / FCF1.90x
    Interest Coverage10.57x

    Returns and Efficiency

    Return on invested capital is -3.87% over the last 12 months, against a 5-year average of 12.31%.

    Return on Equity (ROE)-29.62%
    Return on Assets (ROA)-7.51%
    Return on Invested Capital (ROIC)-3.87%
    Return on Capital Employed (ROCE)-3.86%
    ROE (5Y Average)23.10%
    ROA (5Y Average)8.12%
    ROIC (5Y Average)12.31%
    Asset Turnover0.56x
    Inventory Turnover3.23x
    Receivables Turnover6.16x
    Cash Conversion Cycle125 days

    Scores

    GILD has an Altman Z-Score of 4.00, in the safe zone above 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.

    Altman Z-Score4.00
    Altman Z ZoneSafe
    Piotroski F-Score8 of 9
    Piotroski StrengthStrong

    Income Statement

    Revenue of $30.99B over the last 12 months is up 6.54% from the 12 months before.

    Revenue$30.99B
    Revenue Growth (YoY)+6.54%
    Gross Profit$24.77B
    Operating Income-$2.36B
    Pretax Income-$2.53B
    Net Income-$3.86B
    EBITDA$1.29B
    EBIT-$1.52B
    Reported EPS (TTM)-$0.31

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 25.36% of the $51.41B in total assets.

    Cash and Equivalents$6.44B
    Total Debt$26.23B
    Net Debt$19.79B
    Net Debt Per Share$15.94
    Working Capital$4.55B
    Shareholder Equity$13.04B
    Book Value Per Share$10.50
    Tangible Book Value-$8.70B
    Total Assets$51.41B
    Total Liabilities$38.45B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $699.00M of capital spending, operating cash flow left $13.78B of free cash flow.

    Operating Cash Flow$14.48B
    Capital Expenditures$699.00M
    Free Cash Flow$13.78B
    FCF Per Share$11.10
    Depreciation and Amortization$2.81B
    Dividends Paid$4.10B
    Share Repurchases$1.37B

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -7.62%, against a 5-year average of 26.21%.

    Gross Margin79.93%
    Operating Margin-7.62%
    Pretax Margin-8.18%
    Net Margin-12.47%
    EBITDA Margin4.17%
    EBIT Margin-4.91%
    FCF Margin44.47%
    Gross Margin (5Y Average)77.64%
    Operating Margin (5Y Average)26.21%
    Net Margin (5Y Average)18.14%

    Growth

    Revenue grew 2.57% a year over 3 years, and EPS 3.88% a year.

    Revenue Growth (3Y CAGR)+2.57%
    Revenue Growth (5Y CAGR)+3.58%
    EPS Growth (3Y CAGR)+3.88%
    EPS Growth (5Y CAGR)+2.83%
    FCF Growth (3Y CAGR)+4.26%
    FCF Growth (5Y CAGR)+4.69%
    Operating Income Growth (3Y CAGR)+10.99%
    Book Value Per Share Growth (2Y CAGR)-0.17%

    Revenue and profit by year

    Dividends and Yields

    GILD pays out 27.88% of earnings as dividends.

    Dividend Per Share (Annual)$3.28
    Dividend Yield1.93%
    Payment ScheduleQuarterly
    Dividend Growth (3Y CAGR)+2.67%
    Dividend Growth (5Y CAGR)+3.04%
    Payout Ratio27.88%
    FCF Payout Ratio29.77%
    FCF Yield6.52%
    Buyback Yield0.51%
    Shareholder Yield2.45%

    Full dividend history

    Stock Splits

    The last split was a 2-for-1 forward split on Jan 28, 2013.

    Last Split DateJan 28, 2013
    Split TypeForward split
    Split Ratio2:1

    Peer Position

    Against 12 similar companies, GILD has the 3rd highest P/S and the 10th highest dividend yield.

    P/S Ratio6.8x vs 4.1x median
    ROIC-3.87% vs 13.95% median
    Revenue Growth (Trailing 4 Quarters, YoY)+6.54% vs +5.31% median
    Dividend Yield1.93% vs 2.69% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 6.79% and EPS growth at 11.48% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+6.79%
    EPS Growth Forecast (2Y CAGR)+11.48%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About GILD

    What is GILD's market cap?

    Gilead Sciences has a market cap of $207.86B. Its enterprise value, which adds debt and subtracts cash, is $227.65B.

    How many shares of GILD are outstanding?

    Gilead Sciences has 1.24B shares outstanding. The count is down 0.08% from a year earlier.

    Does GILD pay a dividend?

    Yes. Gilead Sciences pays $3.28 a share a year, a dividend yield of 1.93%.

    How much debt does GILD have?

    Gilead Sciences has $26.23B of total debt and $6.44B of cash and equivalents, a net debt position of $19.79B.